Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber
NCT02874326
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
15
Enrollment
OTHER
Sponsor class
Conditions
Hereditary Hemorrhagic Telangiectasia
Gastrointestinal Hemorrhage
Anemia
Interventions
DRUG:
Octreotide LAR
Sponsor
Radboud University Medical Center
Collaborators
[object Object]